Tyler Martin | Chief Executive Officer
Adjuvance Technologies

Tyler Martin, Chief Executive Officer, Adjuvance Technologies

Dr. Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine adjuvant company, with headquarters in Lincoln, NE, based on intellectual property from Memorial Sloan Kettering Cancer Center in New York, NY. Prior to Adjuvance, he held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax. He has led teams that filed more than 100 Investigational New Drug (IND) Applications including two adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-B.


Pre-congress Workshops, April 6 @ 2:00


Presentations include:
  • Perspectives of vaccine adjuvant discovery and development, and funding opportunities for adjuvant research
  • Optimal approaches for clinical evaluation of Small Molecule Immune Potentiators
  • Adjuvants that specifically drive immune responses required for challenging vaccines
    • TB
  • Next Generation Saponin Adjuvants for Improved Vaccines
  • Influenza: Identification of new adjuvants inducing potent and durable humoral immune responses
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates